SCHEMBL24569769

SCHEMBL24569769

N#Cc1cnc2ccc(Cl)nc2c1Cl

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSNK1A1 P48729 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
RPS6KA5 O75582 1/20 0.39
RPS6KA4 O75676 1/20 0.39
PIN1 Q13526 1/20 0.36
ALDH1A1 P00352 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CHRM4 P08173 1/20 0.32
SRC P12931 5/20 0.32
LRRK2 Q5S007 2/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
EGFR P00533 1/20 0.31
DYRK1A Q13627 1/20 0.31
CYP11B2 P19099 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3374333 0.83 CSNK1A1 (0.38) CSNK1A1CLK4PIN1ALDH1A1NPSR1
SCHEMBL30083629 0.83 CSNK1A1 (0.38) CSNK1A1CLK4RPS6KA5RPS6KA4PIN1
SCHEMBL24569776 0.83 CSNK1A1 (0.38) CSNK1A1CLK4RPS6KA5RPS6KA4PIN1
SCHEMBL3278716 0.80 SRC (0.39) SRCEGFR
SCHEMBL6644636 0.77 SRC (0.38) CSNK1A1CLK4PIN1ALDH1A1TDP1
SCHEMBL6646968 0.76 KDM4E (0.39) CSNK1A1CLK4PIN1ALDH1A1NPSR1
SCHEMBL6642446 0.74 PTK2 (0.44) LRRK2EGFRDYRK1A
SCHEMBL21494203 0.73 EGFR (0.33) EGFR
SCHEMBL14905208 0.73 EGFR (0.39) EGFR
SCHEMBL14978386 0.73 ALDH1A1 (0.41) ALDH1A1ADORA1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116921-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2024-04-11 US disclosed
EP-4267137-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 Enliven Inc. (US) 2023-11-01 EP disclosed
WO-2022266425-A1 3-CYANO-QUINOLINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116921-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ERBB2, FGFR2, ERBB3 CSNK1A1 850/4885CLK4 2768/4885RPS6KA5 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.